BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20251120T001401EST-5373lnv9lG@132.216.98.100
DTSTAMP:20251120T051401Z
DESCRIPTION:JOINT CORE/EBOH EPI Seminar Series Fall 2025\n\nThe Seminars in
  Epidemiology organized by the Department of Epidemiology\, Biostatistics 
 and Occupational Health at the 涩里番 School of Population and Global Heal
 th is a self-approved Group Learning Activity (Section 1) as defined by th
 e maintenance of certification program of the Royal College of Physicians 
 and Surgeons of Canada. Physicians requiring accreditation\, please comple
 te the Evaluation Form and send to admincoord.eboh [at] mcgill.ca ()adminc
 oord.eboh [at] mcgill.ca ( )\n\nPatrick R. Lawler\, MD\, MPH\, FRCPC\n\nCl
 inician-Scientist and Associate Professor|\n	涩里番 and Universi
 ty of Toronto\n\nWHEN: Monday\, October 27\, 2025\, from 3:30-4:30pm\n	WHER
 E: Hybrid | 2001 涩里番 College\, Rm 1140 &\n	Onsite at 5252 boul. de Maiso
 nneuve - 3rd floor\, 3B Kitchen | Zoom\n	**Note: Patrick Lawler will be pre
 senting in-person at CORE\n	聽\n\nSpeaker Bio\n\nDr. Patrick Lawler is direc
 tor of the Cardiac Intensive Care Unit at the 涩里番 Health Cen
 tre in Montreal\, and also a staff cardiologist at Toronto General Hospita
 l in Toronto\, both in Canada. He is an Associate Professor of Medicine at
  涩里番 and the University of Toronto. His research employs Bay
 esian adaptive platform randomized clinical trials\, clinical epidemiology
 \, and translational methods. He has a focus on methods to identify hetero
 geneity of treatment effect in clinical trials. He has led randomized clin
 ical trials in acutely/critically ill patients\, and has also supported th
 e design and implementation of others. His research has been funded by gre
 ater than $35M from the Canadian Institutes of Health Research\, the U.S. 
 National Institutes of Health\, philanthropy\, and others\, and has been p
 ublished in the New England Journal of Medicine\, JAMA\, the European Hear
 t Journal\, Circulation\, Intensive Care Medicine\, Critical Care Medicine
 \, and elsewhere. He is the chief medical officer at Sparked Inc.\, an ear
 ly-stage Toronto-based microfluidic diagnostic company. He serves on execu
 tive committees for the American Heart Association and as the inaugural as
 sociate editor for cardiac critical care for the American College of Cardi
 ology's open access journal JACC: Advances.\n	\n	Learning Objectives\n\nAt t
 he completion of this talk\, attendees will be able to:\n\n\n	Understand he
 terogeneous treatment effects in randomized controlled trials and their cl
 inical implications\;\n	Develop familiarity with modern statistical methods
  to identify differential treatment responses across patient subgroups in 
 clinical trials including the estimation of individualized treatment effec
 ts\;\n	Consider emerging clinical trial designs built around these framewor
 ks. 聽\n\n\n聽\n\n聽\n
DTSTART:20251027T193000Z
DTEND:20251027T203000Z
SUMMARY:Estimating treatment effects for individual patients using randomiz
 ed controlled trials: Promise and challenges
URL:/epi-biostat-occh/channels/event/estimating-treatm
 ent-effects-individual-patients-using-randomized-controlled-trials-promise
 -and-368484
END:VEVENT
END:VCALENDAR